2.98
-0.095(-3.09%)
Currency In USD
| Previous Close | 3.07 |
| Open | 3.11 |
| Day High | 3.15 |
| Day Low | 2.97 |
| 52-Week High | 19.44 |
| 52-Week Low | 0.97 |
| Volume | 89,866 |
| Average Volume | 161,717 |
| Market Cap | 14.18M |
| PE | 0.71 |
| EPS | 4.19 |
| Moving Average 50 Days | 1.95 |
| Moving Average 200 Days | 2.76 |
| Change | -0.1 |
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025
GlobeNewswire Inc.
Oct 14, 2025 11:00 AM GMT
Non-inferiority trial versus PAXLOVID® assessing safety and efficacy, including rates of disease rebound and incidence of Long COVID development, of ratutrelvir, a ritonavir-free anti-viral treatment Separate single-arm trial assessing safety and eff
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives
GlobeNewswire Inc.
Oct 06, 2025 11:00 AM GMT
NEWTOWN, Pa., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies to target critical threats to human health from resp
Traws Pharma Receives Approval to Proceed with Phase 2 COVID Studies with Ratutrelvir, Expects Results by Year-End 2025
GlobeNewswire Inc.
Aug 18, 2025 11:00 AM GMT
Non-inferiority trial to assess safety and efficacy, including rates of disease rebound and incidence of Long COVID development of ratutrelvir, a ritonavir-free treatment, compared to PAXLOVID® Separate single-arm trial will assess safety and efficac